Lucas Moreno Martín-Retortillo I am a doctor specialized in paediatric cancer. I lead the Paediatric Oncology and Haematology Division of Vall d’Hebrón since 2019, with an outstanding team dedicated to providing the best care to our patients and families, and being national and international reference for numerous paediatric cancers. My goal is to improve cancer treatment so that no children and adolescents die of cancer, and that survivors can live a full life free of sequels Institutions of which they are part Head of group Childhood Cancer and Blood Disorders Vall Hebron Institut de Recerca Clinical Director Paediatric Oncology and Haematology Children's Hospital and Woman's Hospital LinkedIn Email Lucas Moreno Martín-Retortillo LinkedIn Email Institutions of which they are part Head of group Childhood Cancer and Blood Disorders Vall Hebron Institut de Recerca Clinical Director Paediatric Oncology and Haematology Children's Hospital and Woman's Hospital I am a doctor specialized in paediatric cancer. I lead the Paediatric Oncology and Haematology Division of Vall d’Hebrón since 2019, with an outstanding team dedicated to providing the best care to our patients and families, and being national and international reference for numerous paediatric cancers. My goal is to improve cancer treatment so that no children and adolescents die of cancer, and that survivors can live a full life free of sequels
Dr. Lucas Moreno just moved to Barcelona to lead the Paediatric Oncology & Haematology Division at Vall d'Hebron Hospital. He has devoted his career to childhood cancer drug development. His main research interest is in neuroblastoma, one of the most aggressive forms of childhood cancer. After returning from London where he worked at the Royal Marsden Hospital from 2008 to 2012, he created and led the Clinical Trials Unit at Hospital Niño Jesús (Madrid) that became a leading trials unit for paediatric drug development nationally and internationally. He is a key opinion leader in neuroblastoma and drug development in Europe and works for international networks such as SIOPEN (siopen.net) and ITCC (itcc-consortium.org). He leads the BEACON-Neuroblastoma trial open in 10 European countries for relapsed & refractory neuroblastoma. He has been principal investigator of more than 30 clinical trials and has co-authored more than 60 international publications in the field. He provides second opinion consultations for children and adolescents with relapsed/refractory cancers nationally and internationally to facilitate access to early clinical trials and novel agents. He is a keen supporter of incorporating the patient/parents voice into research and clinical practice and has started several projects on quality of life, quality of care, late effects and patient reported outcomes. His favourite conference of the year is the Solving Kids’ Cancer Parent conference because of the excellent interaction between researchers, clinicians and parents.
Projects A phase I trial of ABTL0812 in paediatric patients with advanced cancer including neuroblastoma IP: Lucas Moreno Martín-Retortillo Collaborators: Soledad Gallego Melcón, Cristina Gamez Cenzano, Aroa Soriano Fernández, Luis Riera Soler, Miguel Segura Ginard, Carlota Aguilera Ordoñez Funding agency: Instituto de Salud Carlos III Funding: 826760.77 Reference: ICI21/00076 Duration: 01/01/2022 - 30/06/2026 Implementation and new biomarker development for Personalised Medicine for Childhood Cancers in Spain IP: Lucas Moreno Martín-Retortillo Collaborators: Andrea Vilaplana Blanes, Aroa Soriano Fernández, Aroa Soriano Fernández, Margarita Ortega Blanco, Miguel Segura Ginard, Lorena Valero Arrese, Berta Campos Estela, Raquel Hladun Alvaro, Elena Antima Martinez Saez, Marta Sese Faustino, Estela Carrasco López, Gabriela Guillén Burrieza, Josep Roma Castanyer Funding agency: Instituto de Salud Carlos III Funding: 369260 Reference: PMP21/00073 Duration: 01/01/2022 - 30/06/2026 Next generation personalised medicine for childhood cancers IP: Lucas Moreno Martín-Retortillo Collaborators: Andrea Vilaplana Blanes, Aroa Soriano Fernández, Jessica Camacho Soriano, Lorena Valero Arrese, Raquel Hladun Alvaro, Gabriela Guillén Burrieza Funding agency: Instituto de Salud Carlos III Funding: 214170 Reference: PI21/01661 Duration: 01/01/2022 - 30/06/2026 BEACON-BIO: deep biological characterisation and development of biomarkers for relapsed neuroblastoma IP: Lucas Moreno Martín-Retortillo Collaborators: Andrea Vilaplana Blanes Funding agency: European Science Foundation Funding: 104500 Reference: BEACON-BIO_FKC_2021 Duration: 01/01/2022 - 30/09/2025 Pagination First page « Previous page ‹ Page 1 Page 2 Page 3 Current page 4 Page 5 Next page › Last page »
